CJC-1295 With DAC

COMPOUND OVERVIEW

CJC-1295 With DAC is a long-acting synthetic analogue of growth hormone-releasing hormone (GHRH) featuring a Drug Affinity Complex (DAC) that covalently bonds to circulating albumin in the bloodstream, dramatically extending its half-life to approximately 6–8 days. This sustained-release characteristic makes it a powerful tool for research protocols that require prolonged GH axis stimulation without frequent dosing. It is one of the most potent GHRH analogues available for research, producing extended IGF-1 elevation and continuous GH secretion patterns that differ fundamentally from the pulsatile approach of the Without DAC variant.

MECHANISM OF ACTION

Upon administration, CJC-1295 With DAC undergoes bioconjugation to serum albumin via its DAC lysine moiety, significantly extending plasma half-life. It then acts on pituitary GHRH receptors continuously over days, stimulating persistent (non-pulsatile) GH release. This results in elevated IGF-1 levels for an extended window. The continuous GH release pattern differs from physiological pulsatile secretion, making it a useful research tool for studying the differential effects of sustained vs. pulsatile GH signaling on metabolism, tissue growth, and the somatotropic axis.

RESEARCH APPLICATIONS

• Extended GH axis stimulation research
• IGF-1 elevation and downstream anabolic pathway studies
• Long-duration body composition research protocols
• Comparison studies: sustained vs. pulsatile GH stimulation
• Age-related GH decline and reversal research
• GH-dependent metabolic pathway modulation

KEY RESEARCH FINDINGS

• Research has demonstrated sustained GH elevation for 6–8 days following a single administration
• IGF-1 levels in research models showed dose-dependent increases persisting beyond one week
• Body composition studies using the DAC variant noted favorable lean mass changes over multi-week protocols
• Comparative research between DAC and non-DAC forms demonstrates distinct GH secretion kinetics and metabolic outcomes
• Minimal receptor desensitization reported in short-duration research protocols

STORAGE & HANDLING

• Store lyophilized powder at -20°C; stable up to 24 months
• Reconstitute with bacteriostatic water; store at 2–8°C post-reconstitution
• Use within 28 days of reconstitution
• Avoid freeze-thaw cycling after reconstitution
• Maintain sterile handling conditions throughout research use

SPECIFICATIONS

DISCLAIMER: This compound is sold strictly for laboratory and research purposes only. It is not intended for human consumption, clinical use, or veterinary application. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. For use by licensed researchers and qualified professionals only. You must be 21 years of age or older to purchase.

usaminopeptides.com · For Researcher Inquiries Contact: info@usaminopeptides.com